Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
JPH0333121B2 - - Google Patents
[go: Go Back, main page]

JPH0333121B2 - - Google Patents

Info

Publication number
JPH0333121B2
JPH0333121B2 JP60163536A JP16353685A JPH0333121B2 JP H0333121 B2 JPH0333121 B2 JP H0333121B2 JP 60163536 A JP60163536 A JP 60163536A JP 16353685 A JP16353685 A JP 16353685A JP H0333121 B2 JPH0333121 B2 JP H0333121B2
Authority
JP
Japan
Prior art keywords
cmi
water
dinaphthol
clathrate compound
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP60163536A
Other languages
Japanese (ja)
Other versions
JPS6222701A (en
Inventor
Fumio Toda
Ayako Sekikawa
Hideo Sugi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kurita Water Industries Ltd
Original Assignee
Kurita Water Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kurita Water Industries Ltd filed Critical Kurita Water Industries Ltd
Priority to JP60163536A priority Critical patent/JPS6222701A/en
Publication of JPS6222701A publication Critical patent/JPS6222701A/en
Publication of JPH0333121B2 publication Critical patent/JPH0333121B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Thiazole And Isothizaole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

[産業上の利用分野] 本発明は包接化合物に係り、特に徐放性抗菌剤
等として有用な新規包接化合物に関するものであ
る。 [従来の技術] 各種工場施設の冷却水系或は紙パルプ抄造系等
の水系においては、次のような様々な菌類又は動
植物類のスライムが付着し、様々な障害を引き起
こしている。 冷却水系においては、ズーグレア状細菌、藻
類、糸状菌等のスライムが付着し、熱効率の低
下、通水の悪化、金属材質等の腐食の誘発等の原
因となつている。 紙パルプ抄造系においては、細菌、糸状菌、酵
母等のスライムが主に抄紙工程で発生し、これは
パルプスラリー中に異物として混入・付着して、
製品の品質を低下させるばかりでなく、紙切れを
発生させ、生産効率を大幅に低下させる等の様々
な障害を引き起こす。特に、近年、紙パルプ抄造
系においては、循環水の使用量を高める傾向にあ
り、スライムによる問題はより重要なものとなつ
ている。 海水を利用する火力発電所や製鉄所等の諸工場
の冷却水系の取水口や冷却管の内面には、海水性
藻類、海水性バクテリアやムラサキイガイ、ホヤ
等の生物が付着し、これらの機能低下の原因とな
つている。また付着したこれらの生物は、水圧や
流速等により剥ぎ取られ、熱交換器のチユーブや
ストレーナ等の他の部位の目詰りをも引き起き
し、海水の通水を妨げ装置全体の機能を低下させ
る。 従来、このようなスライム等による障害を防止
するためには、その処理法が比較的簡便なこと、
安価であることから、抗菌剤(スライムコントロ
ール剤)が一般に使用されている。しかして、特
に汎用されている抗菌剤としては、イソチアゾリ
ン系化合物等の水溶性殺菌剤が挙げられる。これ
らのうち、特に下記()で示される−クロロ−
2−メチル−4−イソチアゾリン−3−オン(以
下「CMI」と略称する。)は抗菌力に優れてお
り、冷却水系用、紙パルプ用、水泳プール用等各
種水系用スライムコントロール剤、殺菌剤、殺藻
剤、殺かび剤として広く使用されている。 このCMIは、一般に、 β−チオケトアミドを酢酸エステル等の不活
性有機エステル溶剤中でハロゲン化する、 β置換チオシアノアクリルアミド又はチオサ
ルフアートアクリルアミドを酸で処理してイソ
チアゾロンを得、更にハロゲン化する、 方法で製造されている(特公昭46−21240号公
報)。 [発明が解決しようとする問題点] しかしながら、上記及びの方法のいずれの
場合においては、CMIだけを選択的に得ること
はできず、副生成物として、下記()式で示さ
れる、抗菌力がCMIよりも10倍も劣る、2−メ
チル−4−イソチアゾリン−3−オン(以下、
「MI」と略称する。)、及び抗菌力が全くない塩化
マグネシウム、硝酸マグネシウム等が混入したも
のしか得られない。 しかも従来の技術では、反応生成混合物から
CMIのみを選択的に取り出すことはできず、や
むを得ず抗菌力が劣るMIも混合したままの状態
で使用しているのが実状である。 一方、このようなCMIは、ある程度優れた抗
菌力を有する抗菌剤であるが、極めて皮膚刺激性
が強く、取り扱い上多大な注意が必要であつた。
また、水中に投入して用いる際には、水中の有機
物(アミン、還元性物質等)と反応して活性を失
うため、長期間抗菌活性を維持することが難しか
つた。しかも、水に易溶なため、水中防汚塗料に
配合して使用する場合には、速やかに水中に溶出
するので、その防汚効果を長期間維持することが
できないという問題を有している。 このように、従来一般的に使用されている水溶
性の抗菌剤は、毒性、抗菌活性の低下、水への溶
解性等から、取り扱い、抗菌効果等の面で極めて
不都合を有するものであつた。 [問題点を解決するための手段] 本発明の包接化合物は上記従来の問題点を解決
する、優れた徐放性抗菌剤を提供することできる
包接化合物であつて、CMIと1,1′−ビ−2−ナ
フトールとからなることを特徴とする。 以下本発明を詳細に説明する。 1,1′−ビ−2−ナフトールは下記()式で
示されるものである。以下、これを単に「β−ジ
ナフトール」という。 CMIとβ−ジナフトールとからなる本発明の
包接化合物は、次の(イ),(ロ),(ハ)を原料として製造
される。 (イ) メタノール、エタノール等の水可溶性の溶媒
にβ−ジナフトールを溶解させた溶液。 (ロ) CMI。 (ハ) CMIと不純物等を含む混合物。 即ち、(イ)と(ロ)、又は(イ)と(ハ)とを、水中に徐々

添加して反応させる。これにより、包接化合物は
暗黒色物として析出する。この析出物を常法によ
り、濾過分離し、目的とする包接化合物を得るの
である。 このように、本発明の包接化合物の製造にあた
つては、原料のCMIとして、副生成物等の不純
物を含有するものをそのまま用いても、目的とす
る有効成分のみを選択的に包接した包接化合物が
得られるので極めて有利である。 CMIはゲスト分子として、選択的にホスト分
子であるβ−ジナフトールに包接され、包接化合
物として析出する。このようにして得られる本発
明の包接化合物は、製造条件等により小異はある
ものの、一般には、次の如き反応により、各式の
右辺に示される組成を有する包接化合物として得
られる。 β−ジナフトール+CMI→ β−ジナフトール・CMI このようにして得られる本発明の包接化合物
は、通常は粉末状の固体であり、打錠等の成型も
容易である。またCMIが包接されているので、
毒性が低く、取り扱いが容易である。 本発明の包接化合物は、ゲスト分子である
CMIの徐放性を示すため、徐放性抗菌剤として
使用することができると共に、CMIの粉末化、
安定化、濃縮化等にも役立つものである。更に、
本発明の包接化合物はCMIとβ−ジナフトール
との選択性に優れた反応生成物であるため、
CMIの分離、精製にも用いることができ、その
工業的有用性は極めて高い。 本発明の包接化合物を徐放性抗菌剤として用い
る場合、その使用方法としては以下に示すような
方法が挙げられる。 本剤をカラムに充填し、被処理水を通水す
る。 本剤を水浸透性で水に溶解しない袋やカート
リツジに入れ、水系に浸漬もしくは浮遊させて
使用する。 成型又は粉末状の本剤を水系に分散させて流
す。 塗料、その他の樹脂等と混合して水系等の機
器表面等に塗る。 保護物体の表面に適当な方法により付着させ
る。 [作用] CMIはβ−ジナフトールとの包接化合物とさ
れることにより、固体状態となり、CMIは、本
発明の包接化合物から徐々に水中に溶解してゆく
ようになる。また、CMIは包接されることによ
り、その毒性、皮膚刺激性等が低減される。しか
も使用中に他の物質と反応して抗菌活性が低下す
ることも防止される。 このため、本発明の包接化合物は、CMIの抗
菌活性を極めて長時間維持することができる徐放
性抗菌剤として有効に用いることができる。 [実施例] 以下に本発明を実施例を挙げて更に具体的に説
明するが、本発明はその要旨を超えない限り以下
の実施例に限定されるものではない。 実施例 1 β−ジナフトール・CMIの製造: β−ジナフトール5.05g(1.74×10-2モル)をメ
タノール100mlに溶解したβ−ジナフトール溶液
に、CMIとMIとを含むKATHON886(ロームア
ンドハース社製品)を30.8g(CMIとして2.36
g、1.75×10-2モル)を添加して撹拌したとこ
ろ、暗黒色の析出物が析出した。これを室温で16
時間静置した後、濾紙で濾過して析出物と溶液と
を分離した。 析出物のNMR分析の結果、析出物はモル比で
β−ジナフトール:CMI=1:1、重量比で
65.7:34.3であることが確認された。なお、
KATHON886に含まれていたMI、塩化マグネシ
ウム、硝酸マグネシウムは含まれていないことが
元素分析により確認された。 CMIの溶出試験: 得られたβ−ジナフトール・CMI及び
CMI単独の2種類を、CMI換算で0.1gとなるよ
うに、0.8μメンブレンフイルター袋に入れ、これ
を純水1中に浸漬し、スターラー撹拌しながら
一定時間後のCMI濃度を測定し、その経時変化
を調べた。 結果を第1表に示す。
[Industrial Field of Application] The present invention relates to clathrate compounds, and particularly to novel clathrate compounds useful as sustained-release antibacterial agents. [Prior Art] In water systems such as cooling water systems of various factory facilities or pulp and paper manufacturing systems, slimes of various fungi or plants and animals such as those described below adhere, causing various problems. In the cooling water system, slime such as zooglare bacteria, algae, and filamentous fungi adheres to the cooling water system, causing a decrease in thermal efficiency, poor water flow, and induction of corrosion of metal materials. In the paper pulp manufacturing system, slime from bacteria, filamentous fungi, yeast, etc. is mainly generated during the paper making process, and this slime gets mixed in and adheres to the pulp slurry as foreign matter.
This not only reduces the quality of the product, but also causes various problems such as paper breakage and a significant drop in production efficiency. In particular, in recent years, there has been a trend to increase the amount of circulating water used in paper pulp manufacturing systems, and the problem caused by slime has become more important. Marine organisms such as seawater algae, seawater bacteria, mussels, and sea squirts adhere to the inside surfaces of the cooling water intakes and cooling pipes of thermal power plants, steel mills, and other factories that use seawater, resulting in a decline in their functionality. It is the cause of In addition, these attached organisms are peeled off by water pressure and flow velocity, causing clogging of other parts such as the tubes and strainers of the heat exchanger, blocking the passage of seawater and reducing the functionality of the entire device. let Conventionally, in order to prevent problems caused by slime, etc., it has been necessary to have a relatively simple treatment method.
Antibacterial agents (slime control agents) are commonly used because they are inexpensive. Particularly commonly used antibacterial agents include water-soluble bactericidal agents such as isothiazoline compounds. Among these, -chloro- shown in the following ()
2-Methyl-4-isothiazolin-3-one (hereinafter abbreviated as "CMI") has excellent antibacterial properties and is used as a slime control agent and disinfectant for various water systems such as cooling water systems, paper pulp, and swimming pools. It is widely used as an algaecide and fungicide. This CMI generally involves halogenating a β-thioketoamide in an inert organic ester solvent such as an acetate, treating a β-substituted thiocyanoacrylamide or thiosulfate acrylamide with an acid to obtain an isothiazolone, and further halogenating it. (Japanese Patent Publication No. 46-21240). [Problems to be Solved by the Invention] However, in any of the above methods, it is not possible to selectively obtain CMI alone, and as a by-product, the antibacterial activity shown by the following formula () is obtained. 2-methyl-4-isothiazolin-3-one (hereinafter referred to as
It will be abbreviated as “MI”. ), and those containing magnesium chloride, magnesium nitrate, etc., which have no antibacterial activity, can only be obtained. Moreover, with conventional technology, from the reaction product mixture
The reality is that it is not possible to selectively extract only CMI, and unavoidably, MI, which has inferior antibacterial activity, is used in a mixed state. On the other hand, although such CMI is an antibacterial agent having a certain degree of excellent antibacterial activity, it is extremely irritating to the skin and requires great care when handling.
Furthermore, when used in water, it reacts with organic substances (amines, reducing substances, etc.) in the water and loses its activity, making it difficult to maintain antibacterial activity for a long period of time. Moreover, since it is easily soluble in water, when used in an underwater antifouling paint, it quickly dissolves into the water, resulting in the problem that its antifouling effect cannot be maintained for a long period of time. . As described above, the water-soluble antibacterial agents commonly used in the past have been extremely inconvenient in terms of handling, antibacterial effects, etc. due to toxicity, decreased antibacterial activity, and solubility in water. . [Means for Solving the Problems] The clathrate compound of the present invention is an clathrate compound that can solve the above-mentioned conventional problems and provide an excellent sustained-release antibacterial agent. '-bi-2-naphthol. The present invention will be explained in detail below. 1,1'-bi-2-naphthol is represented by the following formula (). Hereinafter, this will be simply referred to as "β-dinaphthol." The clathrate compound of the present invention consisting of CMI and β-dinaphthol is produced using the following raw materials (a), (b), and (c). (a) A solution in which β-dinaphthol is dissolved in a water-soluble solvent such as methanol or ethanol. (b) CMI. (c) A mixture containing CMI and impurities. That is, (a) and (b), or (a) and (c) are gradually added to water and reacted. As a result, the clathrate compound precipitates as a dark black substance. This precipitate is filtered and separated by a conventional method to obtain the desired clathrate compound. As described above, in producing the clathrate compound of the present invention, even if the raw material CMI contains impurities such as by-products, it is possible to selectively encapsulate only the desired active ingredient. This is extremely advantageous since tangential clathrates are obtained. As a guest molecule, CMI is selectively included in the host molecule β-dinaphthol and precipitates as an inclusion compound. The clathrate compound of the present invention obtained in this manner is generally obtained as an clathrate compound having the composition shown on the right side of each formula by the following reaction, although there are slight differences depending on the manufacturing conditions and the like. β-dinaphthol+CMI→β-dinaphthol/CMI The clathrate compound of the present invention obtained in this manner is usually a powdery solid and can be easily molded into tablets and the like. Also, since CMI is included,
It has low toxicity and is easy to handle. The clathrate of the present invention is a guest molecule
Since CMI exhibits sustained release properties, it can be used as a sustained release antibacterial agent, and it can also be used to powderize CMI.
It is also useful for stabilization, concentration, etc. Furthermore,
Since the clathrate compound of the present invention is a reaction product with excellent selectivity between CMI and β-dinaphthol,
It can also be used to separate and purify CMI, and its industrial utility is extremely high. When the clathrate compound of the present invention is used as a sustained-release antibacterial agent, the following methods may be used. Fill the column with this agent and pass the water to be treated. This drug is placed in a water-permeable, water-insoluble bag or cartridge, and used by immersing or floating it in a water system. Disperse this agent in molded or powdered form into an aqueous system and pour it out. Mix with paint, other resin, etc. and apply to water-based equipment surfaces, etc. Attach it to the surface of the protected object by an appropriate method. [Function] CMI becomes a solid state by forming an clathrate compound with β-dinaphthol, and CMI gradually dissolves in water from the clathrate compound of the present invention. Moreover, by inclusion of CMI, its toxicity, skin irritation, etc. are reduced. Moreover, it is also prevented from reducing antibacterial activity due to reaction with other substances during use. Therefore, the clathrate compound of the present invention can be effectively used as a sustained-release antibacterial agent that can maintain the antibacterial activity of CMI for an extremely long period of time. [Examples] The present invention will be described in more detail below with reference to Examples, but the present invention is not limited to the following Examples unless the gist thereof is exceeded. Example 1 Production of β-dinaphthol/CMI: KATHON886 (Rohm and Haas product) containing CMI and MI in a β-dinaphthol solution prepared by dissolving 5.05 g (1.74 × 10 -2 mol) of β-dinaphthol in 100 ml of methanol. 30.8g (2.36 as CMI)
When the mixture was stirred, a dark black precipitate was deposited. This at room temperature 16
After standing for a period of time, the solution was filtered through filter paper to separate the precipitate and the solution. As a result of NMR analysis of the precipitate, the molar ratio of the precipitate was β-dinaphthol:CMI=1:1, and the weight ratio was
It was confirmed that the ratio was 65.7:34.3. In addition,
Elemental analysis confirmed that MI, magnesium chloride, and magnesium nitrate, which were contained in KATHON886, were not contained. Elution test of CMI: Obtained β-dinaphthol/CMI and
Two types of CMI alone were placed in a 0.8 μ membrane filter bag so that the weight was 0.1 g in terms of CMI, immersed in pure water 1, and the CMI concentration was measured after a certain period of time while stirring with a stirrer. We investigated changes over time. The results are shown in Table 1.

【表】 第1表から明らかなように、CMI単独では
フイルター袋の浸漬と同時にCMIが溶出したが、
の包接化合物ではCMIは徐々に溶出している。
従つて、本発明の包接化合物は、抗菌剤として用
いた場合、有効成分であるCMIの溶出が徐々に
起こる徐放効果により抗菌活性が長時間維持され
ることが明らかである。 [効果] 以上詳述した通り、本発明の包接化合物は、
CMIをβ−ジナフトールにより包接したもので
あり、CMIの粉末化、安定化、濃縮化、分離、
精製等に利用することができる上に、特に包接さ
れたCMIを有効成分とする徐放性抗菌剤として、 有効成分が徐々に水中に溶出するため抗菌活
性を長時間維持することができる、 固体状であるため、打錠成型等の成型が可能
であり、取り扱いが容易である、 殺菌剤の毒性、皮膚刺激性等が低減されるこ
とから、作業環境が改良され、安全性が向上され
る、 有効成分が他の物質と反応し抗菌活性が低下
するのが防止される、 等の優れた効果を奏し、工業的に極めて有用であ
る。
[Table] As is clear from Table 1, when using CMI alone, CMI was eluted at the same time as the filter bag was immersed, but
In the clathrate compound, CMI gradually elutes.
Therefore, it is clear that when the clathrate compound of the present invention is used as an antibacterial agent, its antibacterial activity is maintained for a long time due to the sustained release effect in which the active ingredient CMI gradually elutes. [Effect] As detailed above, the clathrate compound of the present invention has the following effects:
CMI is clathrated with β-dinaphthol, and CMI is powdered, stabilized, concentrated, separated,
In addition to being able to be used for purification, etc., as a sustained-release antibacterial agent containing clathrated CMI as an active ingredient, it can maintain antibacterial activity for a long time because the active ingredient gradually dissolves into water. Since it is a solid, it can be molded into tablets and other forms, making it easy to handle.It also reduces the toxicity and skin irritation of disinfectants, improving the working environment and increasing safety. It has excellent effects such as preventing the active ingredient from reacting with other substances and reducing its antibacterial activity, making it extremely useful industrially.

Claims (1)

【特許請求の範囲】[Claims] 1 5−クロロ−2−メチル−4−イソチアゾリ
ン−3−オンと1,1′−ビ−2−ナフトールとの
包接化合物。
1 Inclusion compound of 5-chloro-2-methyl-4-isothiazolin-3-one and 1,1'-bi-2-naphthol.
JP60163536A 1985-07-24 1985-07-24 Slow-acting antimicrobial agent Granted JPS6222701A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP60163536A JPS6222701A (en) 1985-07-24 1985-07-24 Slow-acting antimicrobial agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP60163536A JPS6222701A (en) 1985-07-24 1985-07-24 Slow-acting antimicrobial agent

Publications (2)

Publication Number Publication Date
JPS6222701A JPS6222701A (en) 1987-01-30
JPH0333121B2 true JPH0333121B2 (en) 1991-05-16

Family

ID=15775743

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60163536A Granted JPS6222701A (en) 1985-07-24 1985-07-24 Slow-acting antimicrobial agent

Country Status (1)

Country Link
JP (1) JPS6222701A (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0725743B2 (en) * 1988-01-26 1995-03-22 栗田工業株式会社 Inclusion compound
JPH0725645B2 (en) * 1988-03-07 1995-03-22 栗田工業株式会社 Antibacterial composition
JP2805817B2 (en) * 1989-04-19 1998-09-30 栗田工業株式会社 Sterilizing composition
JP2722043B2 (en) * 1993-07-21 1998-03-04 純正化學株式会社 Novel intermolecular compound and method for producing the same
JP2717620B2 (en) * 1993-07-27 1998-02-18 純正化學株式会社 Method for producing organic solvent solution of dichloroglyoxime
WO2000020372A1 (en) 1998-10-08 2000-04-13 Nippon Soda Co., Ltd. Molecular compounds containing novel carboxylic acid derivatives as the constituent compound
US9149045B2 (en) * 2010-12-07 2015-10-06 Kimberly-Clark Worldwide, Inc. Wipe coated with a botanical emulsion having antimicrobial properties

Also Published As

Publication number Publication date
JPS6222701A (en) 1987-01-30

Similar Documents

Publication Publication Date Title
JPH0146497B2 (en)
US4952398A (en) Biocidal composition with copper algicide
JPH0257046B2 (en)
US3844760A (en) Composition for and method of treating water
US4505889A (en) Protracted release microbiocidal article for aqueous systems
ZA200502875B (en) Active bromide containing biocidal compositions and their preparation.
EP2448414A2 (en) Stabilized and activated bromine solutions as a biocide and as an antifouling agent
JPH0333121B2 (en)
JP3077268B2 (en) Novel clathrate compound and its production method
JP3077243B2 (en) Inclusion compound and method for producing the same
JPH0434987B2 (en)
EP0326262B1 (en) Clathrate compound and a method of producing the same
EP0648415B1 (en) Clathrate compound including water-soluble microbicide
US4996220A (en) Method of producing a clathrate compound
US20020136781A1 (en) Method for making colloidal cupric compounds and their uses
JPH08229569A (en) Aqueous slime treatment method
JP2722043B2 (en) Novel intermolecular compound and method for producing the same
JPH0349907B2 (en)
JPH01197406A (en) clathrate compound
JPS63175068A (en) synthetic resin products
JPH0641101A (en) New clathrate compound and its produciton
EP0181068A2 (en) Halogen release biocide
JP3082264B2 (en) Method for producing clathrate compound and clathrate compound
JPS6361925B2 (en)
JPH0459095A (en) Decomposition treatment of drainage containing triorganotin compound

Legal Events

Date Code Title Description
LAPS Cancellation because of no payment of annual fees